Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sung Won, Choi, Jonggi, Kim, Seung Up, Lim, Young-Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273642/
https://www.ncbi.nlm.nih.gov/pubmed/34157830
http://dx.doi.org/10.3350/cmh.2021.0179
_version_ 1783721410912321536
author Lee, Sung Won
Choi, Jonggi
Kim, Seung Up
Lim, Young-Suk
author_facet Lee, Sung Won
Choi, Jonggi
Kim, Seung Up
Lim, Young-Suk
author_sort Lee, Sung Won
collection PubMed
description Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
format Online
Article
Text
id pubmed-8273642
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-82736422021-07-22 Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma Lee, Sung Won Choi, Jonggi Kim, Seung Up Lim, Young-Suk Clin Mol Hepatol Review Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development. The Korean Association for the Study of the Liver 2021-07 2021-06-23 /pmc/articles/PMC8273642/ /pubmed/34157830 http://dx.doi.org/10.3350/cmh.2021.0179 Text en Copyright © 2021 by The Korean Association for the Study of the Liver https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Lee, Sung Won
Choi, Jonggi
Kim, Seung Up
Lim, Young-Suk
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
title Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
title_full Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
title_fullStr Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
title_full_unstemmed Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
title_short Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
title_sort entecavir versus tenofovir in patients with chronic hepatitis b: enemies or partners in the prevention of hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273642/
https://www.ncbi.nlm.nih.gov/pubmed/34157830
http://dx.doi.org/10.3350/cmh.2021.0179
work_keys_str_mv AT leesungwon entecavirversustenofovirinpatientswithchronichepatitisbenemiesorpartnersinthepreventionofhepatocellularcarcinoma
AT choijonggi entecavirversustenofovirinpatientswithchronichepatitisbenemiesorpartnersinthepreventionofhepatocellularcarcinoma
AT kimseungup entecavirversustenofovirinpatientswithchronichepatitisbenemiesorpartnersinthepreventionofhepatocellularcarcinoma
AT limyoungsuk entecavirversustenofovirinpatientswithchronichepatitisbenemiesorpartnersinthepreventionofhepatocellularcarcinoma

Ejemplares similares